- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the safety of abiraterone acetate with 4 alternative steroid treatment strategies related to symptoms associated with mineralocorticoid excess toxicities (ie, hypokalemia and/or hypertension) during the first 24 weeks of treatment in asymptomatic, chemotherapy-naïve, mCRPC subjects.
Critère d'inclusion
- Metastatic Castration Resistant Prostate Cancer